

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

PCT

(43) International Publication Date
8 February 2007 (08.02.2007)(10) International Publication Number
WO 2007/014941 A3

(51) International Patent Classification:

A61K 31/47 (2006.01) C07D 215/22 (2006.01)

A61P 31/04 (2006.01) C07D 215/18 (2006.01)

(21) International Application Number:

PCT/EP2006/064858

(22) International Filing Date: 31 July 2006 (31.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

05107164.5 3 August 2005 (03.08.2005) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A Division of Janssen-Cilag Campus de Maigremont, BP 615, 27106 Val de Reuil Cedex (FR). **PASQUIER, Elisabeth, Thérèse, Jeanne** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A Division of Janssen-Cilag Campus de Maigremont, BP 615, 27106 Val de Reuil Cedex (FR). **LANÇOIS, David, Francis, Alain** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A Division of Janssen-Cilag Campusde Maigremont, BP 615, 27106 Val de Reuil Cedex (FR). **ANDRIES, Koenraad, Jozef, Lodewijk, Marcel** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KOUL, Anil** [IN/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BACKX, Leo, Jacobus, Jozef** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **MEERPOEL, Lieven** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS



(57) **Abstract:** Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula (I), a pharmaceutically acceptable acid or base addition salt, a quaternary amine, a stereochemically isomeric form, a tautomeric form or a *N*-oxide form thereof, wherein R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1 to 3; s is O to 4; R^2 is hydrogen; halo; alkyl; hydroxy; mercapto; optionally substituted alkyloxy; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted; Ar; Het or a radical of formula (II), R^3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is O to 4; R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or R^4 and R^5 may be taken together including the N to which they are attached; R^6 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R^6 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; r is 1 to 5; R^7 is hydrogen, alkyl, Ar or Het; R^8 is hydrogen, alkyl, hydroxyl, aminocarbonyl, mono- or di(alkyl)aminocarbonyl, Ar, Het, alkyl substituted with one or two Het, alkyl substituted with one or two Ar, Het-C(=O)- or Ar-C(=O)-; provided that when the R^3 bearing radical is placed in position 3 of the quinoline moiety; R^7 is placed in position 4 and R^2 is placed in position 2 and represents hydrogen, hydroxy, mercapto, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula (III), then s is 1 to 4.



WO 2007/014941 A3



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
29 March 2007

(48) Date of publication of this corrected version:
31 May 2007

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report*

(15) **Information about Corrections:**
see PCT Gazette No. 22/2007 of 31 May 2007
Previous Correction:
see PCT Gazette No. 18/2007 of 3 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.